CAMBRIDGE, England, Dec. 2, 2025 /PRNewswire/ -- bit.b io, the global leader in cell programming technology, today announces the publication of its 2025 Corporate Sustainability Report, reaffirming ...
A reliable supply of consistent and physiologically relevant motor neurons is fundamental to the study and screening of potential treatments for motor neuron diseases ioMotor Neurons also offer an ...
SEATTLE, May 27, 2026--(BUSINESS WIRE)--Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a ...
Dr Hermann Hauser, serial entrepreneur, co-founder of Amadeus Capital Partners and founder of semiconductor company, Arm Ltd, and gene-sequencing company, Solexa / Illumina, joins as chair of the ...
CAMBRIDGE, England, February 19, 2026--(BUSINESS WIRE)--Following a record Q4 in sales volume and the successful closing of $50 million in new funding, bit.bio is leveraging its economies of scale to ...
Researchers can now order their mutation of choice in bit.bio’s opti-oxTM powered human-iPSC derived cells, receiving consistent, defined, cryopreserved products that can be immediately incorporated ...
BlueRock Therapeutics, a clinical-stage cell therapy company, and bit.bio, a synbio firm, signed a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T ...
The report provides evidence-based metrics aligned with the UN Sustainable Development Goals (SDGs), highlighting year-over-year improvements. It demonstrates how sustainability is integrated across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results